v3.26.1
Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Abstract]    
Research and engineering expenses $ 29,483 $ 33,627
Clinical expenses 35,564 22,960
In-process research and development expenses 5,000 0
Total research and development expenses 70,047 56,587
General and administrative expenses 17,290 14,796
Other segment items (4,379) (3,140)
Net loss $ 82,958 $ 68,243